InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $2.740 0.54 (24.55%)+
Announcement
Release
19 Aug 2026 8:01AM
Price at Release
$2.200
Full Release
download
Summary
AVITA Medical, Inc. announced positive results from the PermeaDerm-I clinical study, which demonstrated that their biosynthetic wound matrix, PermeaDerm, provides a 70% economic advantage over cadaveric allograft for wound temporization. The study showed that PermeaDerm delivers comparable clinical outcomes, reducing preparation time significantly by 95.7%, and did not attribute any adverse events to its use. Conducted across 11 U.S. burn centers, the study supports PermeaDerm as a modern, efficient, and economically viable alternative to traditional allografts, strengthening AVITA's position in the acute wound care market.
Key Points
  • AVITA Medical announces positive results from PermeaDerm-I study.
  • PermeaDerm shows 70% economic advantage over allograft.
  • The study demonstrates comparable clinical outcomes to allografts.
  • PermeaDerm reduces preparation time by 95.7% compared with allografts.
  • No adverse events were attributed to PermeaDerm during the study.
  • AVITA Medical is a leading therapeutic acute wound care company.
  • The study enrolled 40 patients across 11 U.S. burn centers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.